Amputations under PMB Regulations: The Latest CMScript

By HEOR Staff Writer

January 20, 2023

Council for Medical Schemes latest CMScript focusing on amputations under PMB regulations. Amputation, the removal or loss of a body part, can drastically alter a person’s life. It impacts an individual’s mobility, work capabilities, social interactions, and independence. This article explores the causes of amputations, preventative measures, and the journey towards recovery and rehabilitation.

Life After Amputation: Recovery and Rehabilitation

Amputations due to traumatic and crush injuries, severe burns, diabetes mellitus, peripheral artery diseases, severe infections, and cancers must be funded in line with the PMB Regulations. This would include diagnosis, treatment, and care of PMBs irrespective of the member’s option.

Prosthetic limbs replace the function of the lost body part and are recommended based on the type of amputation, the patient’s general health, and the tasks expected to be performed using the prosthesis. However, not all individuals are suitable for a prosthetic limb, particularly those with serious health conditions such as heart failure.

Preventing Amputations

Preventing amputations involves addressing the underlying issues that may necessitate such a procedure. Lifestyle modifications, including a balanced diet, regular exercise, quitting smoking, and maintaining stable blood sugar, blood pressure, and cholesterol levels, are essential. Regular examination of the legs and feet for sores or changes in skin colour or temperature is also crucial.

Reference url

Recent Posts

Inflation Reduction Act Impact on Clinical Trial Investment Trends

By João L. Carapinha

March 26, 2026

The Inflation Reduction Act Impact is becoming evident in early data on industry-sponsored clinical trials. A recently published JME article examines how the Drug Price Negotiation Program (DPNP) introduced by the IRA may be altering investment incentives for biopharmaceutical innovation.
EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application Amid Regulatory Hurdles

By João L. Carapinha

Anavex Life Sciences has withdrawn its marketing authorization application for blarcamesine in early Alzheimer’s disease following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). EU Alzheimer Approval Challenges remain a significant hurdle for ...
South Africa Health Reform: Revitalizing the Crisis-Stricken Sector

By João L. Carapinha

South Africa health reform is urgently needed to reverse the deepening crisis in the country’s public and private health sectors. Sustained real-term declines in public per-capita spending, massive provincial debt, critical staff shortages, and uncontrolled private-sector cost escalation are coll...